Asciminib Roll-over Study
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
85 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
Capital Federal, Argentina
Recruiting
- Novartis Investigative Site
Graz, Austria
Recruiting - Novartis Investigative Site
Vienna, Austria
Recruiting
- Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Completed - Novartis Investigative Site
São Paulo, São Paulo, Brazil
Completed - Novartis Investigative Site
São Paulo, São Paulo, Brazil
Completed
- Novartis Investigative Site
Varna, Bulgaria
Recruiting
- Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
- Novartis Investigative Site
Chongqing, Chongqing Municipality, China
Recruiting - Novartis Investigative Site
Guangzhou, Guangdong, China
Recruiting - Novartis Investigative Site
Zhengzhou, Henan, China
Recruiting - Novartis Investigative Site
Wuhan, Hubei, China
Recruiting - Novartis Investigative Site
Changchun, Jilin, China
Recruiting - Novartis Investigative Site
Xian, Shanxi, China
Recruiting - Novartis Investigative Site
Chengdu, Sichuan, China
Completed - Novartis Investigative Site
Beijing, China
Recruiting - Novartis Investigative Site
Beijing, China
Active, not recruiting - Novartis Investigative Site
Shanghai, China
Active, not recruiting - Novartis Investigative Site
Shenyang, China
Recruiting - Novartis Investigative Site
Tianjin, China
Recruiting
- Novartis Investigative Site
Ostrava, Poruba, Czechia
Recruiting - Novartis Investigative Site
Brno, Czechia
Recruiting
- Novartis Investigative Site
Copenhagen, Denmark
Completed
- Novartis Investigative Site
Bordeaux, France
Recruiting - Novartis Investigative Site
Lyon, France
Recruiting - Novartis Investigative Site
Marseille, France
Recruiting - Novartis Investigative Site
Nantes, France
Recruiting - Novartis Investigative Site
Paris, France
Recruiting - Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Recruiting
- Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Recruiting - Novartis Investigative Site
Jena, Thuringia, Germany
Recruiting - Novartis Investigative Site
Berlin, Germany
Recruiting - Novartis Investigative Site
Kiel, Germany
Recruiting
- Novartis Investigative Site
Milan, MI, Italy
Recruiting - Novartis Investigative Site
Roma, RM, Italy
Recruiting - Novartis Investigative Site
Naples, Italy
Completed
- Novartis Investigative Site
Kobe, Hyōgo, Japan
Active, not recruiting
- Novartis Investigative Site
Beirut, Lebanon
Completed
- Novartis Investigative Site
George Town, Pulau Pinang, Malaysia
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Aug 2022
- Primary completion
- 30 Aug 2030
- Completion
- 30 Aug 2030
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 347
- Registry id
- NCT04877522
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.